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Abstract
Background: Decision support tools build upon comprehensive and timely syntheses of literature. Rapid reviews
may allow supporting their development by omitting certain components of traditional systematic reviews. We
thus aimed to describe a rapid review approach underlying the development of decision support tools, i.e., five
decision boxes (DB) for shared decision-making between seniors living with dementia, their caregivers, and
healthcare providers.
Method: We included studies based on PICO questions (Participant, Intervention, Comparison, Outcome) describing
each of the five specific decision. We gave priority to higher quality evidence (e.g., systematic reviews). For each DB,
we first identified secondary sources of literature, namely, clinical summaries, clinical practice guidelines, and
systematic reviews. After an initial extraction, we searched for primary studies in academic databases and grey
literature to fill gaps in evidence. We extracted study designs, sample sizes, populations, and probabilities of
benefits/harms of the health options. A single reviewer conducted the literature search and study selection. The
data extracted by one reviewer was verified by a second experienced reviewer. Two reviewers assessed the quality
of the evidence. We converted all probabilities into absolute risks for ease of understanding. Two to five experts
validated the content of each DB. We conducted descriptive statistical analyses on the review processes and
resources required.
Results: The approach allowed screening of a limited number of references (range: 104 to 406/review). For each
review, we included 15 to 26 studies, 2 to 10 health options, 11 to 62 health outcomes and we conducted 9 to 47
quality assessments. A team of ten reviewers with varying levels of expertise was supported at specific steps by an
information specialist, a biostatistician, and a graphic designer. The time required to complete a rapid review varied
from 7 to 31 weeks per review (mean ± SD, 19 ± 10 weeks). Data extraction required the most time (8 ± 6.8 weeks).
The average estimated cost of a rapid review was C$11,646 (SD = C$10,914).
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Conclusions: This approach enabled the development of clinical tools more rapidly than with a traditional
systematic review. Future studies should evaluate the applicability of this approach to other teams/tools.
Keywords: Knowledge translation, Costs, Decision support technology, Patient decision aid, Evidence summary,
Policy, Knowledge tools, Scoping review, Rapid review
Background
Knowledge syntheses may serve to summarize the results
of primary studies and may support the development of
knowledge tools/products that are later implemented in
practice, evaluated, and sustained [1]. Rapid reviews are a
type of knowledge synthesis used to produce timely infor-
mation to support health decisions [2]. Compared to more
traditional knowledge synthesis methods, such as system-
atic reviews according to Cochrane [3], rapid reviews
shorten or omit some of the steps from systematic reviews
to achieve results in a more timely manner [2, 4, 5].
Depending on the total body of literature in the area, sys-
tematic reviews can take from 6 to 71 weeks (average
32 weeks) to complete [6], which is often an unacceptable
delay in the context of urgent or pressing decision-
making. Rapid reviews are thus being used increasingly to
address the needs of policy-makers, administrators, or cli-
nicians [7] when resources or time are lacking to conduct
a conventional systematic review [2, 8, 9]. There is
currently no standard or universal methodology for rapid
reviews [10]. A recent study described six different
methodological approaches to conducting rapid reviews
[11], with content and format generally adapted to their
intended use [5, 12].
Knowledge syntheses are extremely valuable in the de-
velopment of shared decision-making tools. The shared
decision-making process is recommended whenever evi-
dence is insufficient to clearly support one health option
over the others, or when proof of benefit is more or less
counter-balanced by proof of harm [13]. During a shared
decision-making process, the clinician and patient dis-
cuss the best evidence on the benefits and harms of each
of the options available to address a patient’s health
problem [13, 14]. Evidence is then typically presented to
patients in the form of a patient decision aid [15] or
other shared decision-making tools such as the decision
box [16, 17] or the Option Grid [18]. Shared decision-
making tools should meet the International Patient
Decision Aid Standards (IPDAS) [19, 20], which imposes
prerequisites on the systematic review process on which
the decision aid will be based. For example, the shared
decision-making tool should synthesize the evidence re-
garding all health options available to a patient facing a
specific health problem. Consequently, several syntheses
are often required to populate a single tool. In addition,
because the shared decision-making tool should present
positive and negative features of each option with an
equal amount of details, less robust sources of informa-
tion often have to be used to present the harms of health
options that are often underreported in scientific
sources. Table 1 sets out the impacts of meeting IPDAS
standards for shared decision-making tools on the re-
view processes to synthesize evidence.
Although rapid reviews have been used in several
studies [4, 5, 21, 22], little is known about their use in
the development of shared decision-making tools.
Consequently, we describe a rapid review approach
underlying the development of five decision boxes (DB)
designed to meet the decision-making needs of
community-dwelling seniors living with dementia, and
of their caregivers and healthcare providers. The five de-
cisions covered were prioritized in an earlier Delphi
study of experts (Poirier A, Philippe Voyer, France
Légaré, Michèle Morin, Holly Witteman, Edeltraut
Kröger, Bernard Martineau, Charo Rodrìguez, Giguere
AMC: Caring for seniors living with dementia means
caring for their caregivers too, in preparation) as some
of the most difficult decisions frequently faced by this
population (list of decisions: Table 2). In the present
study, we specifically describe: (1) the rapid review steps,
and (2) the resources and time required for the review
process and DB prototype design.
Table 1 Impact of certification standards for shared decision-
making tools on the review process
Selected standards for the certification
of shared decision-making tools (IPDAS)
Impact on the review process
The tool describes the options available
for the index decision (level 1).
▸ Several interventions need
to be reviewed to design
a single shared decision-
making tool.
The tool describes the positive and
negative features of each option
in equal detail (levels 1 and 2).
▸ Less robust sources of
information need to be
used when there is a lack
of evidence or detail (e.g.,
harms of an intervention).
The tool allows users to compare
the negative and positive features
of available options (level 3).
▸ All probabilities need to
be transformed into
absolute risks with a
common denominator, to
allow the comparison of
benefits and harms, as well
as the various options.
The tool enables the comparison
of outcome probabilities using
the same denominator (level 3).
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Methods
Study design
This is a descriptive study of the steps to implement a
rapid review approach as part of the creative process of
developing five decision boxes (henceforth DB).
Time resources and expertise
We defined the successive project steps and asked re-
viewers to self-report the time required to complete each
of these steps, at the end of each working day, in a
Google Drive worksheet (Google sheets) [23]. The first
author (MAL) collected this data for each DB and from
all reviewers. We used a Dropbox platform to share
project documents.
Rapid review process
We used four specific strategies to shorten the review
process. The first strategy involved having a single re-
viewer conduct literature searches and study selection.
The second strategy consisted of searching a limited num-
ber of databases selected for content relevance with regard
to each of the studied decisions. The third strategy con-
sisted of using an “overview of reviews” approach, by
searching for secondary literature sources first. The fourth
strategy consisted of engaging several reviewers in data ex-
traction and having them mutually review their results as
part of the process to minimize the risk of one reviewer
misinterpreting the results extracted. The following sec-
tions provide more details on the strategies used.
Step 1: searching for evidence
For each DB, a single reviewer conducted a two-stage litera-
ture search. The reviewer consulted an information special-
ist to develop the search strategies (Fig. 1). The reviewer
initially searched for secondary sources of literature and,
once data was extracted from these sources, searched for
primary studies to fill any gaps in the evidence relative to a
particular health option. The searches comprised both grey
literature sources and academic databases.
Search for secondary sources of literature We searched
two online clinical summaries: Dynamed and UpToDate.
We chose Dynamed because these summaries are ac-
cessible without costs at our university, and UptoDate
out of habit, since we used to access them at no cost.
We also searched clinical practice guidelines [e.g.,
Canadian Neurological Sciences Federation, CCCDTD4,
Canadian Task Force, AHRQ, Scottish Intercollegiate
Guidelines Network (SIGN), National Institute for
Health and Care Excellence (NICE), American Academy
of Neurology], and systematic reviews. We conducted
the search for systematic reviews in the Cochrane
Central Register of Controlled Trials (CENTRAL) and in
PubMed (NLM) using the built-in systematic review
search filter (Additional file 1: Search strategies). These
searches allowed us to list most of the available health
options to be considered for each of the five targeted de-
cisions. Because the health options may not all be re-
ported in scientific sources of information, and to ensure
the comprehensiveness of this list of options, several dis-
cussion, and brainstorming sessions were conducted
with the principal investigator (PI) responsible for the
project (AMCG) first, and then with all the review team
members. We then extracted data from these sources
and critically reviewed the available evidence for each
health option.
Search for primary studies Where evidence was lacking
from secondary literature sources, we searched for pri-
mary literature sources using the electronic databases rele-
vant to each decision, including PubMed, The Cochrane
Library, Cinahl, EMBASE, and APA PsycNET. The search
strategies combined keywords from controlled vocabulary
as well as free text to optimize the identification of rele-
vant reports. We also scanned the references cited in the
included primary and secondary literature sources.
When we found no benefits or harms related to a
health option in these academic databases, we conducted
additional searches in grey literature using the Google™
search engine. We searched the websites of professional
associations and government (i.e., Quebec Ministry of
Health, Ministry of Justice, Alzheimer Society, CADTh,
Nutt and Sharpe, Public curator—curateur.gouv.qc.ca,
INESSS, educaloi.qc.ca).
Table 2 Inclusion criteria for each decision box (legend: SwD
seniors living with dementia, P participants, I intervention, C
comparative group, O outcomes)
Titles of the decision boxes (DBs) Inclusion/exclusion criteria
(PICO question)
DB1. Choosing a support option
to decrease the burden of
caregivers of SwD or to improve
their quality of life
(P) Informal caregivers of SwD, (I) any
intervention, (C) usual care or any
alternative intervention, (O) burden or
quality of life measured with validated
scale, or any validated measure
related to any of the quality of life
domains
DB2.Choosing a treatment to
manage agitation, aggression,
or psychotic symptoms in SwD
(P) SwD, (I) any intervention, (C) usual
care or any alternative intervention, (O)
psychotic symptoms, aggression, agitation
DB3. Deciding whether or not
to stop driving following a
diagnosis of dementia
(P) SwD, (I) stopping driving, (C)
continuing to drive, (O) any outcome
DB4. Choosing an option to
maintain or improve the quality
of life of SwD
(P) SwD, (I) any intervention, (C) usual
care or any alternative intervention, (O)
quality of life measured using a validated
scale or any validated measure related to
any of the quality of life domains
DB5. Deciding whether to
prepare advanced directives and
a protection mandate following a
diagnosis of dementia
(P) SwD, (I) preparing advanced care
directives or any other legal
protective supervision measures, (C)
usual care or any alternative
intervention, (O) any outcome
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Step 2: identifying eligible studies
The criteria for inclusion of studies in each of the five
reviews were set iteratively based on preliminary evi-
dence to clarify the scope of the review, notably the
population of interest, the health options, and the out-
comes of interest. These elements were gathered in a DB
preliminary template (www.decisionbox.ulaval.ca). The
template was initially submitted to the PI. Then, a brain-
storming session with all the reviewers involved in the
design of a DB allowed us to explore whether further
clarifications were required before launching a compre-
hensive literature search.
For each DB, we described inclusion criteria based on
a PICO question (Population, Intervention, Comparison
and Outcome) (Table 2) and on study design, giving
priority to systematic literature reviews and, when no re-
view was available, to randomized controlled trials
(RCT). In the absence of robust trials, we included ex-
perimental studies other than RCTs, then qualitative
studies, and in the last resort, non-scientific publications
(e.g., legal texts, government reports, expert opinions).
We included studies published in English, French, and
Spanish and excluded studies in any other language.
A single reviewer screened the references retrieved
using a bibliographic management software (Endnote
version X7.7.1, Clarivate Analytics). Screening was con-
ducted based on the title and abstract first, then on the
full text. When several sources were relevant, we selected
the most relevant by extracting key elements to compare
their applicability to our context (descriptions of the
population and intervention) and their quality (e.g., study
design, number of studies included, and presence of a
meta-analysis for the reviews, dates covered, population,
outcomes, intervention description) in an Excel spread-
sheet (2016 version, Microsoft Corporation).
We did not record the reasons for excluding a
reference.
Step 3: extracting data
From the included studies, a single reviewer extracted
the study design, sample size, characteristics of the study
population, year of publication, and probabilities of
experiencing benefits or harms for each studied health
option in an Excel spreadsheet. If a source reported a
body of evidence amenable to meta-analysis but the
authors did not conduct any, then we performed the
meta-analysis. The PI or the study coordinator (BV)
verified the extraction, ensuring it met the team’s in-
ternal standards of quality, often coaching the reviewer
in knowledge synthesis methodology during this stage.
Fig. 1 Steps of the rapid review process leading to the design of the decision box prototype
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Step 4: assessing the quality of the included studies
Quality of evidence was assessed for each benefit or harm
extracted from quantitative studies using the GRADE
approach (Grading of Recommendations Assessment,
Development and Evaluation) [24–26]. Assessments were
based on four criteria (risk of bias, precision, consistency,
and directness of study results) and led to a level of confi-
dence in the results rated as “high,” “moderate,” “low,” or
“very low.” When an included systematic review reported
GRADE assessments, we reported these assessments dir-
ectly in the DB. When an included systematic review did
not report any GRADE assessment but reported risks of
bias of the primary studies included, then we used those
risks of bias assessments to complete the GRADE assess-
ment. When a systematic review did not report any as-
sessment of the quality of evidence, we completed both
risks of bias and GRADE assessments. We assessed the
risks of bias of RCTs and before-and-after trials using the
Cochrane Risk of Bias Tool [8]. For observational studies
(case-control and cohort), we used the Newcastle-Ottawa
Scale [27]. For qualitative studies or non-experimental
information sources, we did not conduct any quality as-
sessment to speed the review process.
For each benefit and each harm, a first reviewer com-
pleted the GRADE and risk of bias assessments, which
were verified by a second experienced reviewer (BV).
Any discrepancies between reviewers were resolved by
consensus first, or in a team meeting with the PI, if a
consensus could not be reached. These meetings served
as a coaching opportunity to further the expertise of the
team in knowledge synthesis methodology. We produced
general directives for GRADE assessments as the result
of this process and published them for the team in a
Google Drive folder.
Step 5: analyzing data
Whenever possible, the probabilities extracted were trans-
formed into absolute risks (AR) and absolute risk differ-
ences (ARD=AR in intervention group −AR in control
group). For dichotomous outcomes, we extracted the AR
in the intervention and control groups where available.
When we found a statistically significant effect and the
raw data was not available to compute AR and ARD (e.g.,
when only odds ratio, relative risk, or hazard ratio were
available in a report), we mentioned that the intervention
had statistically significant positive impacts, without
providing any figures on the extent of this impact. For
continuous outcomes, we extracted the standardized
mean differences (SMD) presented in the articles where
available. If the SMD was not reported in the article, we
calculated it using the means and standard deviations in
the intervention and control groups. Using a published
methodology [28], we then converted the SMD to an ef-
fect size (Cohen’s d), which was in turn used to calculate
the correlation coefficient (r) [r = d/√ (d2 + 4)]. Then,
we used correlation coefficient (r) to calculate the
success rate of the intervention group (0.5 + r/2), the
success rate of the control group (0.5 − r/2), and the
ARD using a web calculator [13]. These transforma-
tions were carried out by a single reviewer and were
verified by a second reviewer (BV) and a biostatisti-
cian (PHC).
To determine the time necessary to complete the
knowledge syntheses, we calculated the number of work
hours at each step. The length of time required for train-
ing and coaching was included in these calculations. We
converted these figures into an equivalent number of
weeks, using 35 h/week as the reference. We then calcu-
lated descriptive statistics for these figures. We also esti-
mated the costs associated with hiring each reviewer,
taking into account their salary (range: C$10.08 to 44.50
per hour, including benefits). We estimated the costs of
graphical design of the BDs based on an hourly rate of
C$60 per hour. Importantly, we do not report the costs
associated to the time of the PI, information specialist
and biostatistician, and neither do we report the costs of
ordering of references, as our research centre and uni-
versity provide these resources at no costs.
Step 6: expert validation
Between one and four experts reviewed each DB content
for validation purposes. Epistemic experts were selected,
i.e., people with “a capacity to provide strong justifica-
tions for a range of propositions in a domain” [29]. Some
of the experts selected also had performative expertise,
i.e., “a capacity to perform a skill well according to the
rules and virtues of a practice” [29]. We summarized all
the comments received for each DB in a single docu-
ment, noting our decision whether to modify the DB to
address each comment and returned the summary docu-
ment to the experts to keep them engaged in the process
until they are involved again at the tailoring and updat-
ing steps (not reported here).
Decision box prototype design
The results from the five knowledge syntheses were
reported in DB templates, which are designed in such a
way as to help weigh the benefits/harms of all options in
light of the patient’s individual health status, as previ-
ously published [16, 17, 30]. The DB is tailored to the
needs of each type of user, as it includes a version
designed for clinicians (C-DB) and a lay version for
patients/caregivers (P-DB). The C-DB is designed as a
continuing education activity. It provides clinicians with
scientific information that they can review carefully prior
to patient consultations. It is more succinct than the
P-DB and allows clinicians to appraise the evidence
critically by describing the design and participants of
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included studies and by synthesizing study limitations
using the GRADE approach [31]. The P-DB, on the
other hand, is designed for use during consultations to
encourage discussion and to be left with the patient and
caregiver for review afterwards. It is distinct from the
C-DB as it presents the information in complete
sentences, in non-technical language, features larger font
sizes, and comprises a value clarification exercise and an
instrument to screen for decisional conflict. The P-DB
design is inspired by the Ottawa Decision Support
Framework [32] as well as current international stan-
dards for decision aids [21].
Once the content was adapted to fit into each tem-
plate, we sent it to a graphic designer who prepared
printable versions of each decision box.
Results
Description of studies
Results of the search
Depending on the DB, we identified between 104 and
406 references and selected 15 to 26 of them (Table 3).
The number of references screened was highest for DB1
(support for caregivers), and the number of selected
studies was highest for DB2 (agitation, aggression, and
psychotic symptoms). We identified between 2 and 10
health options per DB and extracted between 11 and 62
health outcomes per DB (Table 3). Notably, we found
more benefits than harms in DB5 (advanced directives).
By contrast, we found more harms than benefits in DB3
(driving cessation). For the other DBs, the number of
outcomes was generally evenly divided between harms
and benefits.
Included studies
The number of included studies and the proportion of
studies of each type (reviews, RCTs, non-randomized tri-
als, qualitative studies, and non-scientific publications,
e.g., legal texts, government reports, and expert opin-
ions) varied across the five DBs (Table 3).
Of the 33 systematic reviews included in the 5 DBs, 24
(73%) included a meta-analysis. Of the 12 non-scientific
publications cited in the DBs, 9 (75%) were included in
DB5 (advanced directives). DB4 (quality of life) was
mostly based on systematic reviews and RCTs while DB3
(driving cessation) was based on 2 systematic reviews
and 14 non-randomized controlled trials. The non-
scientific publications comprised expert opinion (n = 1),
reports (n = 2), books (n = 1), websites (e.g., website of
the Curateur public du Quebec responsible for protect-
ing incapacitated individuals) (n = 1), and legal docu-
ments (n = 7). Three qualitative studies were used, two
in DB4 and one in DB1.
Extraction
The number of extracted health outcomes was highest
for DB1 (n = 62), followed by DB2 (n = 58).
Quality assessment using the GRADE approach
Overall, we completed 124 GRADE quality assess-
ments, with numbers of assessments ranging from 9 to
47, depending on the DB (Table 3). For 53 of the out-
comes, we did not complete any GRADE assessment,
either because the outcomes were reported in qualita-
tive research studies (17 outcomes) or in non-scientific
literature (20 outcomes), or because the outcome was
Table 3 Description of the references screened, studies included, options studied, and outcomes retrieved for each decision box
DB1-caregiver DB2-agitation DB3-driving DB4-QoL DB5-advanced directives TOTAL
Number of references identified 406 237 104 252 111 1010
Number of studies included 23 26 16 20 15 100
Systematic reviews 12 15 2 3 1 33
Non-systematic reviews 1 2 0 1 0 4
RCTs 3 5 0 14 2 24
Non-randomized trials 5 2 14 0 3 24
Qualitative studies 1 0 0 2 0 3
Non-scientific publications 1 2 0 0 9 12
Number of health options 7 10 2 5 2 25
Number of health outcomes 62 58 11 29 17 177
Total number of benefits 42 29 3 23 10 107
Total number of harms 20 29 8 6 7 70
Number of GRADE quality assessments 47 45 11 12 9 124
Number of outcomes for which a GRADE
evaluation was not possible
15 13 0 17 8 53
Number of experts who provided comments 3 5 3 4 3 18
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not supported by any evidence (e.g., time required to
attend psychotherapy) (16 outcomes).
Time required
We separated the activities leading to the creation of the
prototypes into two: (a) the rapid review process, and (b)
decision box prototypes design. We defined the rapid re-
view process as the period starting when we initiated the
preliminary search of the literature to the end of the in-
tegration of experts’ inputs. We defined the decision box
prototype design as a stage that included adapting con-
tent (e.g., reading level) and tailoring graphic design to
each type of user (clinicians and patient/caregivers). The
entire project required a total of 3300 h. Of these, 2800
were required for the rapid review process and 500 for
the DB prototypes design.
Depending on the DB, the rapid review process
required an equivalent of 7 to 31 weeks for a single
reviewer working full-time (Table 4). On average, an
equivalent of 19 weeks (SD = 10) full-time was required
to complete a single rapid review, representing approxi-
mately 4.8 months. These estimates comprise the time
required for question refinement, inclusion criteria se-
lection, search strategy development, but do not com-
prise the time of the PI, biostatistician, and information
specialist. The final data extraction step was the most
time-consuming, taking an average of 8 weeks for a
single DB (SD = 6.8). The rapid review in support of
DB5 (advanced directives) required the least time
(7 weeks) of the five. The rapid reviews for DB1 (support
for caregivers) and DB2 (agitation, aggression, and
psychosis) required the most time (30 and 31 weeks, re-
spectively). Depending on the DB, the experts’ com-
ments were incorporated into the DB within 0.8 to
1.6 weeks. Based on these times, and excluding the time
spent by the PI and biostatistician, we estimated that the
cost of a single review ranged from C$1925 to C$30,130
(mean ± SD; C$11,646 ± 10,914).
During the decision box prototype phase, a senior re-
search associate initially adapted the reading level and
content to each type of user, which required 4.5 to
25.5 h per DB (mean ± SD, 18 ± 8 h). A graphic designer
then created the printable color version of each DB, re-
quiring on average 25 h/DB (SD: 14 h) (range: 11 to
47 h/DB). In total, we estimate that an average of
20 weeks (SD: 11) was required to complete both the
review and the prototype design processes for each
DB (range: 8 to 32 weeks, depending on the DB)
(Table 4). Based on these times, we estimate that the
cost of developing a prototype based on the rapid re-
view results ranged from C$1194 to C$3304 (mean ±
SD; C$2188 ± 982).
Overall, the costs of the whole of the activities
comprising the rapid review process and decision box
Table 4 Number of weeks required for each step of (a) the rapid review process, and (b) Decision box prototypes design for each
decision box (considering 35 h/week for a single person)
Step DB1-caregiver DB2-agitation DB3-driving DB4-QoL DB5-advanced directives Mean (SD)
A/Rapid review process
Search for secondary literature sources 0.4 0.4 0.7 0.8 0.6 0.6 (0.2)
First selection (secondary sources) 0.4 0.8 0.2 0.6 0.4 0.5 (0.2)
Preliminary extraction 2 0.8 0.9 3.4 0.6 1.5 (1.0)
Search for primary literature sources
and grey literature
2.4 2.6 1.0 2.4 0.8 1.8 (0.8)
Second selection (primary studies) 2.0 2.3 1.0 2.0 1.0 1.7 (0.5)
Final extraction 14.8 17.3 1.3 6.0 1.1 8.1 (6.8)
Quality assessment 3.0 3 1.4 1.0 0.8 1.8 (1)
Redaction 1 1 1 1 1 1 (0)
Data analysis and transformation 3 1.2 0.8 0.4 0.4 1.2 (0.97)
Integration of expert input and formatting
of references
0.8 1.6 0.8 0.8 0.8 1 (0.3)
Total number of weeks (A, review processes) 30 31 9 18 7 19 (10)
B/decision box prototype design
Adjustments to reading level and content 0.4 0.7 0.1 0.7 0.6 0.5 (0.2)
Graphic design 1.3 1.0 0.5 0.3 0.3 0.7 (0.4)
Total number of weeks (B, prototype design) 1.7 1.7 0.6 1.0 0.9 1 (0.4)
Total time (A + B) 32 33 10 19 8 20 (11)
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prototypes design ranged from C$3581 to C$27,335
(mean ± SD; C$13,429 ± 9024).
Human resources and expertise
Ten reviewers were responsible for reviewing a specific
DB, often in teams of two for a single DB (Table 5).
They conducted literature searches, study selection and
extraction, and drafted the DB content. To ensure the
tools would be relevant to users, three of the reviewers
were potential users of the DB, as they were undergradu-
ate medical students. The reviewers were supervised by
the PI and the project coordinator (BV) who holds a
Doctorate in epidemiology (BV).
We asked content experts (physician-geriatrician, nurse,
informal caregivers, managers of community-based or in-
stitutional organizations, pharmacist, and social worker)
to review and provide feedback on the content of each DB
before beginning work on the graphic design (Table 5).
The content of each DB was reviewed by between 3 and 5
experts (Table 3). They made various comments, includ-
ing suggestions about new references to consider; infor-
mation to add about the evidence presented, such as drug
doses and length of interventions; additional interven-
tions; benefits or adverse effects of an intervention; and
the possibility of transforming the probabilities of certain
benefits and harms. For DB2 (agitation, aggression, and
psychotic symptoms), three experts had serious concerns
about the evidence presented relative to medications and
asked that the increased risk of death in patients taking
atypical antipsychotics be added. One of these experts also
asked that we include a section about the conditions that
need to be verified before starting any pharmacological
treatment for behavioral and psychological symptoms of
dementia (BPSD). The experts’ concerns regarding the
current inappropriate drug prescription for BPSD in pri-
mary care led us to remove the evidence on the impact of
these options from the DB. In DB4 (quality of life), two
experts suggested including a number of additional treat-
ment/intervention options. Other minor comments by the
experts consisted of grammar corrections, rewording of
some sentences to improve understanding, and removal of
information they considered less relevant (e.g., they
suggested removing the use of a therapeutic robot to im-
prove quality of life as it is not yet available in Canada for
community-based seniors with dementia).
Project management
During the course of the study, the reviewers who lacked
training in the conduct of systematic reviews attended
some formal training of the Cochrane for systematic
review author, and team workshops led by the PI on
GRADE study quality assessment. These basic training
sessions were subsequently complemented with informal
coaching by the PI and study coordinator (BV). At the
Table 5 Human resources required




▸ PhD ecotoxicology; professor in the Department of
Family Medicine and Emergency Medicine; systematic
review author; Cochrane-certified trainer
for systematic review authors
▸ Plan the review process
▸ Train team members in systematic
reviewing (in groups and individually)
▸ Organize team meetings
▸ Liaise with the graphic designer
▸ Critically revise all DB content
Project coordinator ▸ Research associate (pharmacist, PhD epidemiology)
with experience in the conduct of one systematic review
▸ Act as primary resource to all team
members
▸ Liaise with the biostatistician
▸Transform probabilities
▸ Revise the GRADE assessments
Reviewers (n = 10) ▸ 4 undergraduate students (1 in psychology, 3 in medicine)
▸ 2 PhD students (psychology, clinical and biomedical
sciences); each of them with experience in the conduct
of one systematic review
▸ 1 postdoctoral fellow (PhD neuropsychology) with
experience in the conduct of one systematic review
▸ 3 research assistants (PhD nutrition sciences, MSc public
health, PhD epidemiology)
▸ Conduct all review steps
▸ Liaise with information specialist
▸ Work in teams for larger DBs
Graphic designer ▸ Specialization in the design of professional training
and health promotion materials
▸ Prepare the final graphic version
of each DB
Biostatistician ▸ MSc biostatistics ▸ Confirm data transformation
Experts
(n = 10)
▸ 5 healthcare providers: 1 physician (geriatrician), 2
nursing experts, 1 pharmacist, 1 social worker
▸ 1 informal caregiver
▸ 2 managers of community-based or institutional
organizations
▸ Provide input and make suggestions
to improve the DBs
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start of each new stage of the review (e.g., selection, ex-
traction), each reviewer’s work was revised iteratively by
the PI and the coordinator, in the presence of the re-
viewer, ensuring it met the team’s internal standards of
quality, so as to enhance the team’s expertise and the
quality of their work.
Data synthesis for decision boxes
To facilitate understanding of the probabilities presented
by users, we presented numeric estimates of the effect of
an intervention into absolute risks whenever possible. A
number of the AR were already available in some of the
included studies, however, we had to calculate the SMD
or absolute risk differences for others. We did not trans-
form 107 outcomes (between 1 and 37 per DB), either
because the results were not statistically significant or
because they were non-quantifiable. This last aspect is
particularly important for DB5, which presents several
legal aspects that have not been reported on in scientific
studies and could thus not be quantified with regard to
risks and benefits. Since some of the probabilities could
not be transformed, we reported data in absolute risk re-
duction for 70 outcomes (25 for DB1, 22 for DB2, 10 for
DB3, 8 for DB4, and 5 for DB5) out of the 177 reported.
Discussion
In this study, we describe an approach for conducting
rapid reviews to populate shared decision-making tools.
We examine the resources required to complete five
specific rapid reviews conducted using this approach for
patients affected by dementia. We highlight the require-
ments of shared decision-making tools, which have
repercussions on the review process underpinning these
tools, notably the need to review the evidence on all
available health options for every tool and the need to
transform probabilities according to best practices in
risk communication. We also describe several strategies
to speed up the review process, notably a preliminary
search of secondary literature sources and execution of
several review steps by a single reviewer with verification
by a second reviewer. For the five specific rapid reviews
in our study, we describe how a team of ten reviewers
with various backgrounds and expertise, directed by a PI
with extensive experience in review methodology and
coordinated by an epidemiologist, performed the reviews
within 7 to 31 weeks, depending on the review. The
study also describes the specialized resources that are
called on at each stage: an information specialist for
literature searches, a biostatistician for GRADE assess-
ments and data transformations, and a graphic designer
to create the printable tools. The study shows wide vari-
ations in the number of resources across reviews, likely
due to variations in the number of outcomes reviewed
and due to the availability of systematic reviews with
meta-analyses to describe the benefits and harms of each
of these options.
The proposed rapid review approach enabled the devel-
opment of five tools for shared decision-making—decision
boxes—that users (clinicians, patients, caregivers) may
find easy to understand. Indeed, we propose a strategy to
improve user understanding of the benefits and harms of
each of the health options by transforming all probabilities
into absolute risks. Absolute risks have been shown to im-
prove statistical literacy and understanding of probabilities
in both doctors and patients [33]. Overall, the approach
documented herein is an example of a specific use of rapid
reviews, the need for which has been expressed by health
system decision-makers (Ministry of Health and Social
Services in Quebec, Canada) [34, 35]. Our approach also
offers the possibility to present quality assessments of the
included studies and to focus on topics prioritized by
practicing health care providers; two elements deemed
crucial in decision-making [35]. Moreover, the involve-
ment of content experts was very valuable to ensure the
applicability of the results within the local context of
implementation.
Among the strategies that we used to shorten the re-
view process, we chose to search a limited number of
databases selected for content relevance. Limiting the
number of databases searched has been previously
highlighted as a potential cause of bias [36], however, a
recent study reported that a vast majority of relevant
studies can be found within a limited number of data-
bases and that there are no changes in results when the
search comprises more databases [37]. Some researchers
have also previously reported that manual searches of
reference lists and contacts with experts may be a more
effective way to acquire information on all performed
trials more quickly than through comprehensive biblio-
graphic database searches [38, 39], since published
reviews never include all trial results [40]. In a study on
the attitudes and perceptions of users toward rapid
reviews, users perceived that a well-conducted rapid re-
view might produce evidence as valid as that produced
through a more traditional systematic review approach
[41]. To the best of our knowledge, our strategy to use
an “overview of reviews” approach, by searching for sec-
ondary literature sources first, has not been reported
previously in the context of rapid reviewing. Our strat-
egy to engage several reviewers at the time so they can
mutually review their results allowed us to train the re-
viewers while validating review results and normalizing
our approach across several tools/reviewers. Some of
these strategies have been previously reported [22].
The average time required to complete the 5 reviews
was 19 weeks, which is similar to the time reported in
rapid reviews [12, 42]. Notably, a recent study reports a
median review time of about 15 weeks per review, based
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on empirical observations made when completing 12
rapid reviews on various topics related to policy, system,
and processes of care [42]. We are aware of a single
study reporting the time required to develop 12 patient
decision aids based on the results of Cochrane system-
atic reviews, which required 4 h/decision aid [43]. The
strategies that we implemented to speed up the review
process thus cause a significant reduction in the
resources required to complete the reviews compared to
traditional systematic review processes that have been
reported to take 32 weeks on average [6]. The ap-
proaches used to conduct reviews influence their costs,
which have been reported to vary from £25,000–140,000
[approximately from C$42,000 to C$234,000] [44] and
up to a quarter of a million US dollars [approximately
C$336,000] [45], whereas in this study we estimated the
average cost of a single review to be approximately
C$11,646. Working with a team of experienced re-
viewers may allow limiting the rapid review costs even
more. However, the provision of a training environment
for inexperienced reviewers has a significant value in a
university environment such as the one where we con-
ducted this research.
The time needed to review the literature varied de-
pending on the decision. This could be explained by
variations in the number of references screened for each
decision or by the number of included studies, health
options, or health outcomes for each health option. DB1
and DB2 presented the highest numbers of health
outcomes and were also those that required the most re-
sources, suggesting that the number of outcomes is an
important determinant of the resources required. In
addition to the volume of literature, the rate of pay may
also influence the costs of conducting these rapid re-
views in another team. In addition, some of the costs
un-related to salaries may need to be accounted for: art-
icle ordering, software, teleconferencing, information
specialist, and biostatistician.
For one of the rapid reviews, i.e., on the question of
the benefits and harms of preparing advanced directives
and a protection mandate in case of incapacity (DB5),
we found very limited evidence, which points to the
need for more research in this area. It was also generally
easier to identify data on benefits rather than on harms.
This highlights the need for improved reporting of the
negative impacts of interventions, hinting to publication
bias issue [46].
Strengths and limitations
In this study, we describe the methodology of a rapid re-
view approach, with the aim of furthering the research on
systematic reviews and on the development of shared
decision-making tools. We address some of the limitations
often reported with regard to rapid reviews, particularly
that they lack transparency and use inappropriate report-
ing [7, 47, 48]. As recommended [49], we report the
methodological details of our approach, to allow a
careful examination of the choices we have made and
reproduction of these results. This may provide a
foundation for future rapid review teams, for example,
when planning the resources they need [50]. Another
strength of this report is the detailed documentation
of each step and the careful reporting of review out-
comes (time, resources).
The proposed rapid review approach. Firstly, the infor-
mation specialist was involved as a consultant and did
not conduct the searches, which may have affected the
validity of the searches. Secondly, the experts were not
blinded and so they might have refrained from making
certain observations. Thirdly, the lack of quality ap-
praisal for the qualitative studies included represents a
significant limitation, especially considering the relatively
important number of such studies. Fourthly, we did not
create a flow diagram for each DB, to describe the num-
ber of references from each source and the reasons of
exclusion.
Additional limitations concern the methods used to
describe this work. First, we did not collect data to as-
sess how the proposed approaches to accelerate review
processes affected the quality of the reviews. A subse-
quent study could thus be conducted to compare our re-
sults to those obtained using a traditional systematic
review methodology. One of the challenges of such a
study would be that the current approach consists of a
review of several interventions that require consideration
during the course of decision-making, and this, in itself,
diverges considerably from traditional systematic re-
views. A second limitation is that this work relied on the
reviewers’ self-reporting of the time required at each
step, with risks of bias from misclassification and recall.
It is uncertain to what extent such bias might impact re-
sults. The use of an online reviewing software allowing
the automatic recording of the time at each review step
may have been more reliable. Such reviewing software
might also improve efficiency and limit the errors in data
extraction, which can reach 30% in a single extraction
[51]. While conversions for dichotomous outcomes were
fairly straightforward, we did encounter more difficulties
converting standardized mean differences to absolute
risk differences. The methodology used was simple but
could lead to some biases in favor of the treatment. Be-
cause of this, we believe greater care and time should be
planned on these conversions, involving a biostatistician
and a clinician well versed in the particular scale used.
Conclusions
This detailed description of a rapid review approach may
allow researchers in the future to choose a
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methodological approach and plan the time, costs, and
resources needed when using this approach to produce
shared decision-making tools. We found that an exten-
sive and an experienced team is required to develop sev-
eral tools within a rigid time frame. Reviewer training is
critical and time-consuming, as there is a lack of re-
sources with the appropriate expertise. An assessment of
decision-making needs and rapid review of systematic
reviews on the benefits and harms of multiple health op-
tions to address those needs allows for the development
of decision support tools that meet users’ expectations
in a timely manner. A future study is now required to
test the applicability of this approach to other teams and
topics.
Additional file
Additional file 1: Search strategies used for each of the five decision
boxes. (DOCX 40 kb)
Abbreviations
AR: Absolute risks; ARD: Absolute risk difference; BPSD: Behavioral and
psychological symptoms of dementia; DB: Decision box; GRADE: Grading of
Recommendations Assessment, Development and Evaluation;
IPDAS: International Patient Decision Aid Standards; NOS: Newcastle-Ottawa
Quality Assessment Scale; PI: Principal investigator; PICO: Population,
Intervention, Comparison, Outcome; RCT: Randomized controlled trial;
SD: Standard deviation; SMD: Standardized mean differences; SwD: Senior
living with dementia
Acknowledgements
We wish to acknowledge the contributions of Élizabeth Parenteau, Michel
Moreau Lapointe, Nélia Sofia Domingues, Eyal Derhy, Philippe Jacob, and
Audrey Michaud as reviewers. We also wish to thank Danielle Caron and
Josée Boulet for their help in designing the tool prototypes, and content
experts: Johanne Senneville, Juliette Bruneau, Hugo Lanoux, Dominique
Stibre, Michel Morin, and Michel Cauchon. We also wish to thank Katherine
Hastings for the writing assistance.
Funding
This project was funded by the Ministère de l’Économie, de l’Innovation et de
l’Exportation du Québec and by the Société de Valorisation SOVAR. We also
received in-kind support from the Office of Education and Continuing
Professional Development of Laval University.
Availability of data and materials
The datasets generated or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
AMCG developed the rapid review approach and supervised the review
team. BV helped develop the approach and coordinated the review team.
MAL wrote the first draft of this manuscript with guidance from AMCG and
LC. P-HC and BV conducted statistical analyses. BV, MAL, and EF-B each
conducted a review. PV, EF-B, and EK revised the DB in their capacity as
content experts. MAL, BV, and AMCG performed data collection and analyses.
All the authors revised and approved the final manuscript.
Competing interest
The authors declare that they have no competing interests.
Consent for publication
Not applicable
Ethics approval and consent to participate
Not applicable
Author details
1Department of Family and Emergency Medicine, Laval University, Pavillon
Ferdinand-Vandry, Room 2881, 1050 Avenue de la Médecine, Quebec city,
QC G1V 0A6, Canada. 2Quebec Excellence Center on Aging, St-Sacrement
Hospital, Room L2, 1050, chemin Sainte-Foy, Quebec city, QC G1S 4L8,
Canada. 3Research Centre on Primary Health Care and Services of Laval
University, Quebec City, Canada. 4CHU de Québec Research Centre, Quebec
City, QC, Canada. 5Faculty of Nursing Sciences, Laval University, Quebec City,
QC, Canada. 6University Laval Faculty of Pharmacy, Quebec City, Canada.
7McGill University Department of Family medicine, 5858 Côte-des-Neiges,
Suite 300, Room 328, Montreal QC H3S 1Z1, Canada. 8St. Francois d’Assise
Hospital, 10, rue de l’Espinay, Quebec city, QC, Room 2122-Z, 1050 Avenue
de la Médecine, Quebec City, QC G1L 3L5, Canada.
Received: 2 December 2016 Accepted: 28 February 2017
References
1. Graham ID, Logan J, Harrison MB, Straus SE, Tetroe J, Caswell W, Robinson
N. Lost in knowledge translation: time for a map? J Contin Educ Health Prof.
2006;26(1):13–24.
2. Khangura S, Konnyu K, Cushman R, Grimshaw J, Moher D. Evidence
summaries: the evolution of a rapid review approach. Syst Rev. 2012;1:10.
3. Higgins J, Lasserson T, Chandler J, Tovey D, Churchill R. Methodological
Expectations of Cochrane Intervention Reviews. Cochrane. London; 2016.
4. Khangura S, Polisena J, Clifford TJ, Farrah K, Kamel C. Rapid review: an
emerging approach to evidence synthesis in health technology assessment.
Int J Technol Assess Health Care. 2014;30(1):20–7.
5. Tricco AC, Antony J, Zarin W, Strifler L, Ghassemi M, Ivory J, Perrier L, Hutton
B, Moher D, Straus SE. A scoping review of rapid review methods. BMC
Med. 2015;13:224.
6. Allen IE, Olkin I. Estimating time to conduct a meta-analysis from number of
citations retrieved. Jama. 1999;282(7):634–5.
7. Ganann R, Ciliska D, Thomas H. Expediting systematic reviews: methods and
implications of rapid reviews. Implement Sci. 2010;5:56.
8. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 [updated March 2011]. Chichester: The Cochrane
Collaboration; 2011. www.handbook.cochrane.org.
9. Eden J, Levit L, Berg A, Morton S. Finding what works in health care:
standards for systematic reviews. Washington, DC: National Academies
Press; 2011.
10. Polisena J, Garritty C, Umscheid CA, Kamel C, Samra K, Smith J, Vosilla A.
Rapid Review Summit: an overview and initiation of a research agenda. Syst
Rev. 2015;4:111.
11. Tricco AC, Zarin W, Antony J, Hutton B, Moher D, Sherifali D, Straus SE. An
international survey and modified Delphi approach revealed numerous
rapid review methods. J Clin Epidemiol. 2016;70:61–7.
12. Polisena J, Garritty C, Kamel C, Stevens A, Abou-Setta AM. Rapid review
programs to support health care and policy decision making: a descriptive
analysis of processes and methods. Syst Rev. 2015;4:26.
13. Charles C, Gafni A, Whelan T. Shared decision-making in the medical
encounter: what does it mean? (or it takes at least two to tango). Soc Sci
Med. 1997;44(5):681–92.
14. Giles K. Decision aids for people facing health treatment or screening
decisions. Int J Evid Based Healthc. 2015;13(2):112–3.
15. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, Holmes-Rovner
M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, et al. Decision aids for
people facing health treatment or screening decisions. Cochrane Database
Syst Rev. 2014;1, CD001431.
16. Giguere A, Legare F, Grad R, Pluye P, Haynes RB, Cauchon M, Rousseau F,
Alvarez Argote J, Labrecque M. Decision boxes for clinicians to support
evidence-based practice and shared decision making: the user experience.
Implement Sci. 2012;7:72.
17. Giguere AM, Labrecque M, Haynes RB, Grad R, Pluye P, Legare F, Cauchon
M, Greenway M, Carmichael PH. Evidence summaries (decision boxes) to
prepare clinicians for shared decision-making with patients: a mixed
methods implementation study. Implement Sci. 2014;9:144.
Lawani et al. Systematic Reviews  (2017) 6:56 Page 11 of 12
18. Elwyn G, Lloyd A, Joseph-Williams N, Cording E, Thomson R, Durand MA,
Edwards A. Option Grids: shared decision making made easier. Patient Educ
Couns. 2013;90(2):207–12.
19. Elwyn G, O’Connor A, Stacey D, Volk R, Edwards A, Coulter A, Thomson R,
Barratt A, Barry M, Bernstein S, et al. Developing a quality criteria framework
for patient decision aids: online international Delphi consensus process.
BMJ. 2006;333(7565):417.
20. Joseph-Williams N, Newcombe R, Politi M, Durand MA, Sivell S, Stacey D,
O’Connor A, Volk RJ, Edwards A, Bennett C, et al. Toward minimum
standards for certifying patient decision aids: a modified delphi consensus
process. Med Decis Making. 2013;34(6):699–710.
21. Mbengi RK, Otter R, Mortelmans K, Arbyn M, Van Oyen H, Bouland C,
de Brouwer C. Barriers and opportunities for return-to-work of cancer
survivors: time for action—rapid review and expert consultation. Syst
Rev. 2016;5:35.
22. Watt A, Cameron A, Sturm L, Lathlean T, Babidge W, Blamey S, Facey K,
Hailey D, Norderhaug I, Maddern G. Rapid reviews versus full systematic
reviews: an inventory of current methods and practice in health technology
assessment. Int J Technol Assess Health Care. 2008;24(2):133–9.
23. How to Use the Google Drive Desktop App to Sync Your Files Anywhere.
http://www.howtogeek.com/228989/how-to-use-the-desktop-google-drive-
app/. Accessed 5 Mar 2017.
24. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist
GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. GRADE guidelines: 3. Rating the
quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.
25. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE
guidelines: a new series of articles in the Journal of Clinical Epidemiology.
J Clin Epidemiol. 2011;64(4):380–2.
26. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, Atkins
D, Kunz R, Brozek J, Montori V, et al. GRADE guidelines: 9. Rating up the
quality of evidence. J Clin Epidemiol. 2011;64(12):1311–6.
27. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised
studies in meta-analyses. Ottawa: Ottawa Health Research Institute; 2014. http://
www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 5 Mar 2017.
28. Borenstein M, Hedges L, Higgins J, Rothstein H. Introduction to Meta-
Analysis. Chichester: Wiley; 2009.
29. Weinstein BD. What is an expert? Theor Med. 1993;14(1):57–73.
30. Giguere A, Legare F, Grad R, Pluye P, Rousseau F, Haynes RB, Cauchon M,
Labrecque M. Developing and user-testing decision boxes to facilitate
shared decision making in primary care - a study protocol. BMC Med Inform
Decis Mak. 2011;11:17–26.
31. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y,
Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE
evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;
64(4):383–94.
32. Ottawa Decision Support Framework to Address decisional confilct. https://
decisionaid.ohri.ca/docs/develop/ODSF.pdf. Accessed 5 Mar 2017.
33. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S.
Helping doctors and patients make sense of health statistics. Psychol Sci
Public Interest. 2007;8(2):53–96.
34. Watt A, Cameron A, Sturm L, Lathlean T, Babidge W, Blamey S, Facey K,
Hailey D, Norderhaug I, Maddern G. Rapid versus full systematic reviews:
validity in clinical practice? ANZ J Surg. 2008;78(11):1037–40.
35. Hartling L, Guise J-M, Kato E, Anderson J, Aronson N, Belinson S, Berliner E,
Dryden D, Featherstone R, Foisy M. EPC methods: an exploration of
methods and context for the production of rapid reviews. In: Research
White Paper (Prepared by the Scientific Resource Center under Contract No
290-2012-00004-C). Rockville: Agency for Healthcare Research and Quality
(US); 2015.
36. Tsertsvadze A, Chen YF, Moher D, Sutcliffe P, McCarthy N. How to conduct
systematic reviews more expeditiously? Syst Rev. 2015;4:160.
37. Hartling L, Featherstone R, Nuspl M, Shave K, Dryden DM, Vandermeer B.
The contribution of databases to the results of systematic reviews: a cross-
sectional study. BMC Med Res Methodol. 2016;16(1):127.
38. Oxman AD, Schunemann HJ, Fretheim A. Improving the use of research
evidence in guideline development: 16. Evaluation. Health Res Policy Syst.
2006;4:28.
39. Royle P, Waugh N. Literature searching for clinical and cost-effectiveness
studies used in health technology assessment reports carried out for the
National Institute for Clinical Excellence appraisal system. Health Technol
Assess. 2003;7(34):iii, ix-x, 1-51.
40. Sampling in evidence synthesis. https://rapid-reviews.info/2016/08/17/
sampling-in-evidence-synthesis/. Accessed 5 Mar 2017.
41. Kelly SE, Moher D, Clifford TJ. Expediting evidence synthesis for healthcare
decision-making: exploring attitudes and perceptions towards rapid reviews
using Q methodology. PeerJ. 2016;4:e2522.
42. Peterson K, Floyd N, Ferguson L, Christensen V, Helfand M. User survey finds
rapid evidence reviews increased uptake of evidence by Veterans Health
Administration leadership to inform fast-paced health-system decision-
making. Syst Rev. 2016;5(1):132.
43. Stacey D, Legare F, Lyddiatt A, Giguere AMC, Yoganathan M, Saarimaki A,
Pardo JP, Rader T, Tugwell P. Translating evidence to facilitate shared
decision making: Development and usability of a consult decision aid
prototype. The Patient: Patient–Centered Outcomes Res. 2016;9:571-82.
44. Petticrew M, Roberts H. Systematic reviews in the social sciences: A practical
guide. Malden: Blackwell Publishing Co.; 2006.
45. McGowan J, Sampson M. Systematic reviews need systematic searchers.
J Med Libr Assoc. 2005;93(1):74–80.
46. Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in
published and unpublished studies of health care interventions: a systematic
review. PLoS Med. 2016;13(9):e1002127.
47. Kelly SE, Moher D, Clifford TJ. Quality of conduct and reporting in rapid
reviews: an exploration of compliance with PRISMA and AMSTAR guidelines.
Syst Rev. 2016;5(1):79.
48. Harker J, Kleijnen J. What is a rapid review? A methodological exploration of
rapid reviews in Health Technology Assessments. Int J Evid Based Healthc.
2012;10(4):397–410.
49. Haby MM, Chapman E, Clark R, Barreto J, Reveiz L, Lavis JN. Designing a
rapid response program to support evidence-informed decision-making in
the Americas region: using the best available evidence and case studies.
Implement Sci. 2016;11(1):117.
50. Rapid review summit: then, now, and in the future. https://www.cadth.ca/sites/
default/files/pdf/RR%20Summit_FINAL_Report.pdf. Accessed 5 Mar 2017.
51. Saldanha IJ, Schmid CH, Lau J, Dickersin K, Berlin JA, Jap J, Smith BT, Carini
S, Chan W, De Bruijn B, et al. Evaluating Data Abstraction Assistant, a novel
software application for data abstraction during systematic reviews:
protocol for a randomized controlled trial. Syst Rev. 2016;5(1):196.
Lawani et al. Systematic Reviews  (2017) 6:56 Page 12 of 12
